Kinetic and mechanistic studies of the Staudinger reduction: On the chemistry of aryl phosphazides
Journal of Physical Organic Chemistry · 2023-02 · 36 (2)
DOI: 10.1002/poc.4442 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Physical Organic Chemistry, online erschienen am 07.10.2022. Verfasst von Samantha Y. Corrigan und 1 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Science Foundation.
Abstract (Originalsprache)
The Staudinger reduction of heteroaryl azides containing an N ‐oxide moiety with triphenylphosphine in mixed aqueous/THF solutions yields a mixture of amine and iminophosphorane products. A product analysis study using a combination of 1 H and 31 P NMR spectroscopic techniques indicates that in these systems, even under mild conditions, the amine product is generated, not from the hydrolysis of the iminophosphorane as expected from the standard reaction mechanism, but via hydrolysis of the phosphazide intermediate. The amount of amine generated is dependent on the structure of the starting azides, the composition of solvent, and the reaction conditions. The possible mechanisms of amine formation under acidic, neutral, and basic conditions are discussed.
Förderung
- National Science Foundation
Zitieren
APA
Corrigan, S. Y., & Poole, J. S. (2023). Kinetic and mechanistic studies of the Staudinger reduction: On the chemistry of aryl phosphazides. Journal of Physical Organic Chemistry, 36(2). https://doi.org/10.1002/poc.4442
Vancouver
Corrigan SY, Poole JS. Kinetic and mechanistic studies of the Staudinger reduction: On the chemistry of aryl phosphazides. Journal of Physical Organic Chemistry. 2023;36(2). doi:10.1002/poc.4442
BibTeX
@article{Corrigan2023,
author = {Corrigan, Samantha Y. and Poole, James S.},
title = {Kinetic and mechanistic studies of the Staudinger reduction: On the chemistry of aryl phosphazides},
journal = {Journal of Physical Organic Chemistry},
year = {2023},
volume = {36},
number = {2},
doi = {10.1002/poc.4442}
}
EUVIMED